Prostate Cancer - Bric Drug Forecasts And Treatment Analysis To 2020

GlobalData analysis finds that the prostate cancer therapeutics market in BRIC (Brazil

, Russia, India and China) is attractive and is primarily driven by the growth in the hormone-refractory prostate cancer therapeutics market. The growth in the number of total patients receiving treatment and increase in the annual cost of hormone-refractory prostate cancer therapy is expected to offset the impact of generic erosion in hormone-dependent prostate cancer therapy. The patient volume was driven by growth in treatment usage patterns such as diseased population, treatment seeking population, diagnosis population and prescription population. The annual cost of prostate cancer therapy between 2001 and 2009 was driven by increased uptake of chemotherapy using Taxotere. Expected launch of new therapies such as Provenge (sipuleucel-T) and Jevtana (cabazitaxel) will further drive the annual cost of therapy.

For Sample Pages, please click or add the below link to your browser:

http://www.globaldata.com/reportstore/RequestSamplePages.aspx?ID=Prostate-Cancer--Brazil-China-India-and-Russia-%28BRIC%29-Drug-Drug-Forecasts-and-Treatment-Analysis-to-2020&Title=Pharmaceuticals_and_Healthcare&ReportType=Industry_Report

Hormone therapy using combination of hormone therapies such as LHRH agonists and androgen receptor antagonists is a prominent treatment regime. Taxotere is the current standard of care for patients that stop responding to hormone therapy. The introduction of new therapies for metastatic prostate cancer is expected to expand the market further.

In 2009, the BRIC countries accounted for approximately 4% of the global prostate cancer therapeutics market.

The current competition in the BRIC prostate cancer therapeutics market is weak since none of the drugs are effective enough to address the high unmet needs existing in the market. Taxotere is the only key drug for hormone-refractory prostate cancer. Other drugs such as Provenge and Jevtana are yet to be launched in the countries. Mitoxantrone and estramustine which are also used in chemotherapy have lower efficacy. There are eight key drugs for hormone-dependent prostate cancer. These drugs do not completely address the unmet needs existing in the prostate cancer market. Hormone therapies dominate the prostate cancer therapeutics market, with relatively fewer options for the hormone-refractory prostate cancer therapeutics market. The current therapies cannot deliver the desired overall survival of 36 to 40 months and a progression free survival of 24 months.

GlobalData, the industry analysis specialist, has released its new report, Prostate Cancer - Brazil, Russia, India and China (BRIC) Drug Forecasts and Treatment Analysis to 2020. The report is an essential source of information and analysis on the prostate cancer therapeutics market in the emerging BRIC countries. The report provides comprehensive information on prostate cancer, highlighting the treatment guidelines. It identifies and analyzes the key trends shaping and driving the prostate cancer therapeutics market in Brazil, Russia, India and China. It analyzes the treatment usage patterns in the BRIC prostate cancer therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. The report provides valuable insights into the pipeline products within the global prostate cancer sector. It quantifies the unmet need in the BRIC prostate cancer therapeutics market, highlighting the opportunity for future players.

For further details, please click or add the below link to your browser:

http://www.globaldata.com/reportstore/Report.aspx?ID=Prostate-Cancer--Brazil-China-India-and-Russia-(BRIC)-Drug-Drug-Forecasts-and-Treatment-Analysis-to-2020&ReportType=Industry_Report&coreindustry=Industry_Report&Title=Pharmaceuticals_and_Healthcare

Visit our report store: http://www.globaldata.com

For more details contact:

pressreleases@globaldata.com

North America: +1 646 395 5477

Europe: +44 207 753 4299

+44 1204 543 533

Asia Pacific: +91 40 6616 6782

by: GlobalData

POST COMMENT

Prostate Cancer - Japan Drug Forecasts And Treatment Analysis To 2020 Prostate Cancer - Spain Drug Forecasts And Treatment Analysis To 2020 Medical Coding and Billing Service Providers in US Medical Recruitment In Different Countries Medical Coding and Billing to Small and Large Clinics in US Best Ed Drug Medical Loans For Surgery: Finance For Surgery Lose Weight To Decrease Risk Of Medical Problems How To Last Longer In Bed - Naturally And Without Drugs New Drug Approvals From Fda, 2000-2007 --- Aarkstore Enterprise Acupuncture Versus Western Medicine Drug And Alcohol Treatment Centers Tackle Nicotine Hazardous Drugs-A Question to Mankind